Recent Development of Wnt Signaling Pathway Inhibitors for Cancer Therapeutics
- 35 Downloads
Purpose of Review
Review current understanding of both canonical and non-canonical Wnt signaling in cancer and provide updated knowledge in current clinical trials of Wnt signaling drugs.
Important roles of both canonical and non-canonical Wnt signaling in cancer have been increasingly recognized. Recent clinical trials of several Wnt-signaling drugs have showed promising outcomes. In addition, some drugs that were originally approved for the treatment of other diseases have been recently found to block Wnt signaling, highlighting their potential to treat Wnt-dependent cancer.
Dysfunction of Wnt signaling is implicated in cancer, and targeting Wnt signaling represents a useful approach to treat cancer. Current clinical trials of Wnt signaling drugs have showed promising outcomes, and repurposing the previously approved drugs for other diseases to treat Wnt-dependent cancer requires further studies.
KeywordsSignaling Cancer Canonical Non-canonical Clinical trial FDA approved Wnt/β-catenin Wnt/Ca2+ Wnt/PCP Wnt inhibitor β-Catenin
This work was supported by start-up funds from Western University of Health Sciences to J.H.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 4.Sharma RP. Wingless a new mutant in Drosophila melanogaster. Drosophila Inf Serv. 1973;50:134.Google Scholar
- 15.Kikuchi A, Yamamoto H, Sato A, Matsumoto S. Chapter 2—new insights into the mechanism of Wnt signaling pathway activation. In: Jeon KW, editor. International review of cell and molecular biology, vol. 291. Cambridge: Academic Press; 2011. p. 21–71.Google Scholar
- 16.Schubert M, Holland L. The Wnt gene family and the evolutionary conservation of Wnt expression.In: Madame Curie Bioscience Database [Internet]. Austin (TX): Landes Bioscience; 2000-2013. https://www.ncbi.nlm.nih.gov/books/NBK6212
- 23.• Martinez S, Scerbo P, Giordano M, Daulat AM, Lhoumeau AC, Thome V, et al. The PTK7 and ROR2 protein receptors interact in the vertebrate WNT/planar cell polarity (PCP) pathway. J Biol Chem. 2015;290(51):30562–72 This study revealed a novel molecular mechanism of action of PTK7 in non-canonical WNT/PCP signaling that may promote cell and tissue movements. PubMedPubMedCentralCrossRefGoogle Scholar
- 32.Grainger S, Traver D, Willert K. Chapter eleven—Wnt signaling in hematological malignancies. In: Larraín J, Olivares G, editors. Progress in molecular biology and translational science, vol. 153. Cambridge: Academic Press; 2018. p. 321–41.Google Scholar
- 34.Tan SH, Barker N. Chapter two—Wnt signaling in adult epithelial stem cells and cancer. In: Larraín J, Olivares G, editors. Progress in molecular biology and translational science, vol. 153. Cambridge: Academic Press; 2018. p. 21–79.Google Scholar
- 47.O'Cearbhaill RE, McMeekin DS, Mantia-Smaldone G, Gunderson C, Sabbatini P, Cattaruzza F, et al. Phase 1b of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with carboplatin (C) and paclitaxel (P) in recurrent platinum-sensitive ovarian cancer (OC). J Clin Oncol. 2016;34(15_suppl):2515.CrossRefGoogle Scholar
- 48.• Mita MM, Becerra C, Richards DA, Mita AC, Shagisultanova E, Osborne CRC, et al. Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with paclitaxel (P) in patients (pts) with 1st- to 3rd-line metastatic HER2-negative breast cancer (BC). J Clin Oncol. 2016;34(15_suppl):2516 This article reported the outcomes of phase 1b study of human monoclonal antibody vantictumab in combination with paclitaxel to treat patients with metastatic HER2-negative breast cancer. CrossRefGoogle Scholar
- 49.Messersmith W, Cohen S, Shahda S, Lenz HJ, Weekes C, Dotan E, et al. Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC). Ann Oncol. 2016;27(suppl_6):677P P.CrossRefGoogle Scholar
- 51.• Ng M, Tan DSP, Subbiah V, Weekes CD, Teneggi V, Diermayr V, et al. First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours. J Clin Oncol. 2017;35(15_suppl):2584 This abstract reported provisional results of the first-in-human application of small molecule inhibitor ETC-159 in an ongoing phase 1A/B trial in patients with advanced solid tumors among various cancers. CrossRefGoogle Scholar
- 52.• Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci. 2013;110(50):20224 This paper reported the discovery of LGK974, a potent and specific small-molecule porcupine inhibitor and showed that LGK974 is potent and efficacious in multiple tumor models at well-tolerated doses in vivo, including murine and rat breast cancer models and a human head and neck squamous cell carcinoma model (HN30). PubMedCrossRefGoogle Scholar
- 54.Ko AH, Chiorean EG, Kwak EL, Lenz H-J, Nadler PI, Wood DL, et al. Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX. J Clin Oncol. 2016;34(15_suppl):e15721-e.CrossRefGoogle Scholar
- 56.Cortes JE, Faderl S, Pagel J, Jung CW, Yoon S-S, Koh Y, et al. Phase 1 study of CWP232291 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). J Clin Oncol. 2015;33(15_suppl):7044.Google Scholar
- 57.• Zhang XQ, Hao JJ. Development of anticancer agents targeting the Wnt/beta-catenin signaling. Am J Cancer Res. 2015;5(8):2344–60 This is a systematical review of the potential therapeutic agents that have been developed to date for inhibition of the Wnt/β-catenin cascade. PubMedPubMedCentralGoogle Scholar
- 62.• Le PN, McDermott JD, Jimeno A. Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28. Pharmacol Ther. 2015;146:1–11 This article reviews the preclinical data of OMP-54F28 and ongoing clinical trials of a phase 1a study and three phase 1b studies of OMP-54F28 in advanced solid tumors. PubMedCrossRefGoogle Scholar
- 63.• Jimeno A, Gordon M, Chugh R, Messersmith W, Mendelson D, Dupont J, et al. A first-in-human phase I study of the anticancer stem cell agent ipafricept (OMP-54F28), a decoy receptor for Wnt ligands, in patients with advanced solid tumors. Clin Cancer Res. 2017;23(24):7490–7 This article reported the detailed outcome of phase 1a dose escalation study of OMP-54F28 in human patients with solid tumors. PubMedCrossRefGoogle Scholar
- 64.Smith DC, Gordon M, Messersmith W, Chugh R, Mendelson D, Dupont J, et al. A first-in-human phase 1 study of anti-cancer stem cell (CSC) agent OMP-54F28 (FZD8-Fc) targeting the WNT pathway in patients with advanced solid tumors. Mol Cancer Ther. 2013;12(11):B79.Google Scholar
- 68.El-Khoueiry AB, Ning Y, Yang DY, Cole S, Kahn M, Zoghbi M, et al. A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors. J Clin Oncol. 2013;31(15):a2501.Google Scholar
- 69.Molnar J, Somberg JC. The clinical pharmacology of ethacrynic acid. Am J Ther. 2009;16(1):86-92.Google Scholar
- 81.Tai W-P, Hu P-J, Wu J, Lin X-C. The inhibition of Wnt/β-catenin signaling pathway in human colon cancer cells by sulindac. Tumori J. 2014;100(1):97–101.Google Scholar
- 84.• Monin MB, Krause P, Stelling R, Bocuk D, Niebert S, Klemm F, et al. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway. J Surg Res. 2016;203(1):193–205 This article reported that niclosamide effectively inhibits colorectal cancer cell proliferation in vitro and attenuates colorectal cancer growth in a rodent model, highlighing the potential of niclosamide as a repurposed therapuetic agent in Wnt-dependpend cancer. PubMedCrossRefGoogle Scholar
- 90.• Fako V, Yu Z, Henrich CJ, Ransom T, Budhu AS, Wang XW. Inhibition of wnt/beta-catenin signaling in hepatocellular carcinoma by an antipsychotic drug pimozide. Int J Biol Sci. 2016;12(7):768–75 This article reported a novel application of antipsychotic agent pimozide as a potential therapeutic targeting the Wnt/β-catenin signaling pathway against Hep3B and HepG2 HCC cells. PubMedPubMedCentralCrossRefGoogle Scholar
- 91.Fidahic M, Jelicic Kadic A, Radic M, Puljak L. (2017). “Celecoxib for rheumatoid arthritis.” Cochrane Database of Syst Rev (6).Google Scholar
- 96.Boon EM, Keller JJ, Wormhoudt TA, Giardiello FM, Offerhaus GJ, van der Neut R, et al. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer. 2004;90(1):224–9.PubMedPubMedCentralCrossRefGoogle Scholar